VENUS REMEDIES LTD.

Venus Remedies Ltd has announced the closure of its trading window for all designated persons, effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the period ending June 30, 2026. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Venus Remedies Ltd has utilized its official social media channels (Instagram, Facebook, LinkedIn, and X) to disseminate information to shareholders regarding the mandatory updation of their Know Your Customer (KYC) details. The company has provided direct links to these posts, facilitating easy access for shareholders to comply with the KYC requirements. This proactive communication aims to ensure all shareholder records are current and accurate.

Venus Remedies Limited's R&D unit, Venus Medicine Research Centre (VMRC), has successfully renewed its recognition from the Department of Scientific and Industrial Research (DSIR), Government of India. This renewal confirms VMRC's continued adherence to stringent criteria for in-house R&D, including qualified staff and dedicated research objectives. The recognition supports VMRC's ongoing projects, such as the development of VRP-034, a novel polymyxin formulation with USFDA QIDP designation, and the GASAR resistance surveillance study. This reaffirms the company's commitment to innovation in critical areas like antimicrobial resistance.

Venus Remedies Ltd. announced its 37th Annual General Meeting (AGM) scheduled for August 20, 2026, via video conferencing. The company proposed a final dividend of ₹10 per equity share (100% on face value of ₹10 each), subject to shareholder approval. The record date for dividend eligibility is set for August 7, 2026, with payment to be made within 30 days of AGM approval, subject to tax deduction. The company also appointed M/s C. L Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27.

Venus Remedies Ltd. has announced its 37th Annual General Meeting (AGM) scheduled for August 20, 2026, to be held via video conferencing. The company also proposed a final dividend of ₹10 per equity share (100% on face value of ₹10 each), subject to shareholder approval at the AGM. The record date for determining eligibility for the dividend is set for August 7, 2026, with payment to be made within 30 days of AGM approval, subject to tax deductions. Additionally, M/s C. L Bansal & Associates were appointed as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27.

Venus Remedies Ltd announced the approval of a final dividend of ₹10 per equity share (100% on face value of ₹10 each) subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 20, 2026, via video conferencing. The record date for determining dividend eligibility is August 7, 2026, with payment within 30 days of AGM approval, subject to tax deduction. The company also appointed M/s C. L Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27. Trading window closed from April 1, 2026.

Venus Remedies Ltd. announced a final dividend of ₹10 per equity share (100% on face value of ₹10 each), subject to shareholder approval at the 37th Annual General Meeting (AGM). The AGM is scheduled for August 20, 2026, via video conferencing. The record date for dividend eligibility is August 7, 2026, with payment within 30 days of AGM approval, subject to tax deduction. The company also appointed M/s C. L Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27.

Venus Remedies Ltd. announces appointments and re-appointments of directors. The 37th Annual General Meeting is scheduled for August 20, 2026, via video conferencing. A final dividend of ₹10 (100%) per equity share is proposed, subject to shareholder approval, with a record date of August 7, 2026. The company has appointed M/s C. L Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27.

Venus Remedies Ltd. announced its 37th Annual General Meeting (AGM) scheduled for August 20, 2026, to be held via video conferencing. The company also declared a final dividend of ₹10 (100%) per equity share, subject to shareholder approval at the AGM. The record date for determining dividend eligibility is August 7, 2026, with payment to be made within 30 days of AGM approval, subject to tax deductions. Additionally, M/s C. L Bansal & Associates were appointed as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27.

Venus Remedies Ltd has received marketing authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma. This marks the company's first marketing authorization for Plerixafor globally and supports its strategy to focus on higher-value specialty injectables in regulated markets. The Saudi Arabian pharmaceutical market is projected to grow to USD 17.1 billion by 2033.